Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Benedetta Terziroli Beretta Piccoliis currently collaborating with
Fondazione Epatocentro Ticino (Rif. FET)
Via Soldino, 9
6962 Lugano
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Phase 2b Study in NASH to Assess IVA337 (NATIVE) (Rif. 15000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Phase 2b Study in NASH to Assess IVA337 (NATIVE) (Rif. 15000 202407)
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Emocromatosi ereditaria - A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (Rif. 20000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Emocromatosi ereditaria - A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (Rif. 20000 202407)
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis (TANDEM) (Rif. 25000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis (TANDEM) (Rif. 25000 202407)
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH (Rif. 30000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH (Rif. 30000 202407)
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Epatite autoimmune - ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER) (Rif. 35000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Epatite autoimmune - ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER) (Rif. 35000 202407)
Benedetta Terziroli Beretta Piccoli
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Non-alcoholic Statohepatitis NASH - Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) (Rif. 45000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Non-alcoholic Statohepatitis NASH - Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) (Rif. 45000 202407)